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Abstract
Background: Gene expression of peripheral myelin protein 22 (PMP22) and the epithelial membrane proteins
(EMPs) was found to be differentially expressed in invasive and non-invasive breast cell lines in a previous study.
We want to evaluate the prognostic impact of the expression of these genes on breast cancer.
Methods: In a retrospective multicenter study, gene expression of PMP22 and the EMPs was measured in 249
primary breast tumors by real-time PCR. Results were statistically analyzed together with clinical data.
Results: In univariable Cox regression analyses PMP22 and the EMPs were not associated with disease-free survival
or tumor-related mortality. However, multivariable Cox regression revealed that patients with higher than median
PMP22 gene expression have a 3.47 times higher risk to die of cancer compared to patients with equal values on
clinical covariables but lower PMP22 expression. They also have a 1.77 times higher risk to relapse than those with
lower PMP22 expression. The proportion of explained variation in overall survival due to PMP22 gene expression
was 6.5% and thus PMP22 contributes equally to prognosis of overall survival as nodal status and estrogen
receptor status. Cross validation demonstrates that 5-years survival rates can be refined by incorporating PMP22
into the prediction model.
Conclusions: PMP22 gene expression is a novel independent prognostic factor for disease-free survival and overall
survival for breast cancer patients. Including it into a model with established prognostic factors will increase the
accuracy of prognosis.
Background
Breast cancer is by far the most frequent cancer of
women with about one million new cases every year
worldwide. Even though the prognosis for breast cancer
patients is rather good, it is still the leading cause of
cancer mortality in women causing about 400,000
annual deaths [1]. So far, the most important prognostic
factor is lymph node status, which indicates disease-free
survival and overall survival in breast cancer. The well
defined predictors include the presence of hormone
receptors that predict the response to endocrine therapy
and the HER2 status that predicts the response to
Tratuzumab. However, there is no predictive factor for
chemotherapy that can be clinically used [2]. The prog-
nosis of breast cancer is also far from being precise.
Identification of new prognostic and predictive markers
will not only help patients to receive the proper treat-
ment, it can also provide new therapeutic targets.
The invasive potential of tumor cells reflects the
intrinsic characteristics of tumor cells. Genes involved
in the invasive process might therefore correlate with
outcome of the disease and have certain prognostic and
predictive values. In a previous study, we characterized
the cell lines derived from breast cancer or normal
breast tissues by their invasive ability to penetrate into a
collagen-fibroblast matrix and compared gene expres-
sion profiles of invasive and non-invasive cell lines using
Affymetrix GeneChip technology [3]. Several genes,
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cancer, were identified and validated by RT-PCR. Two
of these genes code for members of a subfamily of small
hydrophobic membrane proteins, namely EMP3 and
P M P 2 2 .B o t ha r eh i g h l ye x p r e s s e di nm o s to ft h ei n v a -
sive cell lines and had very low expression levels in non-
invasive cell lines.
The whole family consists of the peripheral myelin
protein 22 (PMP22) and the epithelial membrane pro-
teins (EMP1, -2, and -3), which are expressed in many
tissues, and have functions in cell growth, differentia-
tion, and apoptosis [4].
We hypothesize that these genes can have prognostic
impacts on breast cancer. The objectives of the study
are defined as the measurement of the expression of the
EMPs and PMP22 in tumor tissues from 249 breast can-
cer patients using real-time RT-PCR, statistical evalua-
tion of their prognostic impacts, and assessment of their
added values to already established prognostic factors.
Methods
Breast cancer patients
This is a retrospective study, including 249 sporadic pri-
mary breast cancer patients from the Department of
Obstetrics and Gynecology, Medical University of
Vienna, Vienna; and the Department of Gynecology and
Obstetrics, Innsbruck Medical University, Innsbruck
(Table 1) from 1987 to 2001. All procedures were
approved by the institutional advisory boards. The age
of the patients ranged from 27 to 89 years with a mean
age of 58 and a median age of 57 at the time of diagno-
sis. All patients underwent a close follow-up scheme
consisting of regular visits with a complete physical
examination. Ultra-sound examination of the abdomen
and chest X-ray were performed every 6 months. Mam-
mography and bone scan were performed every 12
months or in cases of suspect clinical findings. There
were 109 cases of recurrence in the study. Clinical end-
point of recurrent disease was proven histologically or
otherwise indicated by X-ray, computer tomography, or
bone scan as measurable disease. Patients who did not
die from cancer were censored at the date of death.
There were 71 cases of death within the observation
time. The follow-up period ended in 2008 with a med-
ian follow-up time of 85 months.
Specimen characteristics
Fresh tumor biopsies from breast carcinomas were col-
lected during surgery and snap frozen immediately after
the histologic examination of frozen sections. Only sam-
ples consisting of at least 90% tumor tissues were col-
lected. Clinical pathological parameters were determined
at the Department of Pathology, Medical University of
Vienna. Characteristics of tumors are shown in Table 1.
Tumor biopsies were frozen in liquid nitrogen until
further processed.
Total RNA preparation
Tissues were homogenized using a microdismembrator
and dissolved in GI lysis buffer (4 M Guanidine Isothio-
cyanate, 0.5% N-lauroyl-Sarcosine, 10 mM EDTA, 5
mM Sodium Citrate, and 100 μM b-mercaptoethanol).
Total RNA was extracted from tumor biopsy lysates by
isopycnic centrifugation as described previously [5] fol-
lowed by a DNA digestion step of incubation with
RNase-free DNase I (Roche Diagnostic, Mannheim, Ger-
many) at 37°C for 15 minutes. The quality of the RNA
was examined with RNA 6000 Nano Chips and RNA
6000 Nano Reagent & Supplies on a 2100 Bioanalyzer
(Agilent Technologies, Waldbronn, Germany). RNA
concentrations were determined spectrophotometrically.
Reverse transcription (RT)
RT was carried out using Omniscript Reverse Transcrip-
tase kit (Qiagen, Hilden, Germany). The total reaction
volume was 20 μl including 500 ng RNA. The reaction
mixture was incubated at 37°C for 60 min, heated at 95°
C for 10 min and then cooled on ice. The reaction was
diluted 1:4 with water and aliquoted for further analysis.
Real-time PCR
The primers and probes for beta-2-microglobulin were
included in TaqMan PDAR B2 M RNA Control Reagent
(Applied Biosystems, Foster City, CA). For the quantifica-
tions of EMPs, PMP22 and ER, “Assay-on-Demand” kits
(Applied Biosystems) were used (ER: Hs00174860_m1;
EMP1: Hs00608055_m1; EMP2: Hs00171315_m1; EMP3:
Hs00171319_m1 and PMP22: Hs00165556_m1). 5700
Sequence Detection System (Applied Biosystems) was
used for real-time analysis. 4 μl diluted cDNA aliquot
was used as template for PCR in a total volume of 25 μl
including TaqMan Universal PCR Master Mix and the
corresponding probes and primers. The mixture was pre-
incubated at 95°C for 10 min followed by 40 cycles of
two step incubations at 95°C for 15 s and 60°C for 1 min.
All samples were measured in duplicates.
Quantitation of gene expression
The relative quantitation method with standard curves
was used for the calculation of the relative amounts of
mRNAs. A sample with a high expression level of a cer-
t a i ng e n ew a sc h o s e na sc a l i b r a t o r .I t se x p r e s s i o nw a s
defined as 1. A standard curve using serial dilutions of
the calibrator was used to calculate the amount of
RNAs in other samples. Target quantities of all other
samples were expressed as n-fold in relation to the cali-
brator. To correct the quantity differences in the start-
ing RNA samples, the target quantity of certain mRNA
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house keeping gene beta-2-microglobulin in the same
sample.
Estrogen receptor status by expression analysis
Protein levels of estrogen receptor (ER) in tumors were
primarily determined using immunohistochemistry.
Since ER status was missing for 56 samples (22.5%), we
re-determined it using mRNA gene expression values. A
similar procedure was suggested and used in a previous
s t u d y[ 6 ] .W em e a s u r e dt h eE Rg e n ee x p r e s s i o ni na
cohort of breast cancer tissues with known clinical ER
status obtained by immunohistochemistry and used that
value of ER gene expression as cutoff point for ER sta-
tus, which minimized the sum of false positive and false
negative rates.
Statistical analysis
For model building, the following parameters were consid-
ered besides the expression values of the markers analysed:
age at diagnosis, histological type, nodal status, tumor size,
differentiation grade, and estrogen receptor status.
Mean values and 95% confidence intervals for genes
expression were calculated on a logarithmic scale (log2)
and then transformed back to the original scale (Table
1). In order to compare the gene expression between
two or more groups, T-test or one-way ANOVA,
respectively, were performed using the log-transformed
expression as independent variable with subsequent
Bonferroni-Holm correction for multiple testing.
Disease-free survival is defined as time between diagno-
sis of disease and recurrence or distant metastasis. Over-
all survival is defined as time from diagnosis of disease to
death of patients of breast cancer. Patients who died of
causes unrelated to breast cancer were treated as cen-
sored in disease-specific survival analysis. Median follow-
up time was computed by the Kaplan-Meier method with
reverse status indicator as proposed by Schemper and
Smith [7]. For analysis of disease-free and overall survival,
tumors with differentiation grade 1 and 2 were combined
for comparison with those with differentiation grade 3
and tumors with pT1 were compared with those combin-
ing pT2, pT3 and pT4. These groupings were necessary
because of the low number of cases in some subgroups.
Table 1 Patients’ age and histopathological characteristics of tumors
Mean gene expression
Sample number (%) EMP1 EMP2 EMP3 PMP22
249 (100.0) 1.090 0.225 0.115 0.491
Age
≤50 years 84 (33.7) 1.108 0.236 0.113 0.500
>50 years 165 (66.3) 1.081 0.220 0.117 0.487
Histological type
invasive ductal carcinoma 189 (75.9) 1.045 0.216 0.110 0.482
invasive lobular carcinoma 40 (16.1) 1.385 0.280 0.133 0.558
others and unknown 20 (8.0) 1.006 0.220 0.133 0.455
Nodal status
pN0 95 (38.1) 1.128 0.224 0.122 0.524
pN1 124 (49.8) 1.059 0.228 0.110 0.467
unknown 30 (12.1) 1.102 0.217 0.117 0.493
Tumor size
pT1 (<2 cm) 65 (26.1) 1.153 0.226 0.125 0.528
pT2 (2-5 cm) 127 (51.0) 1.011 0.199 0.110 0.453
pT3 (>5 cm) 23 (9.2) 1.024 0.289 0.111 0.514
pT4 14 (5.6) 1.378 0.395 0.127 0.590
others and unknown 20 (8.0) 1.331 0.246 0.116 0.543
Differentiation grade p = 0.005 p = 0.019
G1 34 (13.7) 1.194 0.351 0.147 0.713
G2 123 (49.4) 1.131 0.250 0.116 0.531
G3 71 (28.5) 0.978 0.165 0.100 0.357
unknown 21 (8.4) 1.096 0.171 0.120 0.497
Estrogen Receptor P < 0.0001 p < 0.001 p < 0.001 p < 0.001
positive 133 (53.4) 1.325 0.344 0.141 0.715
negative 116 (46.6) 0.875 0.138 0.092 0.319
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effects, proportional hazards, linearity of effects) were
assessed as follows. First, interactions of pairs of vari-
ables were evaluated by including and testing corre-
sponding product terms. Second, time-dependency of
hazard ratios was accounted for by testing correlation of
scaled Schoenfeld residuals with time [8]. Third, gene
expression was entered into analysis by using the log2-
values instead of categories, and a potential non-linear
effect of gene-expression was tested by including addi-
tional model terms that were derived from a linear-tail
restricted cubic spline. These sensitivity analyses uncov-
ered a time-dependent effect of estrogen receptor status
on tumor-specific survival, which was accounted for by
including a time-dependent covariate defined as the pro-
duct of estrogen receptor status (1 or 0) and the loga-
rithm of survival time. However, this did not alter any
conclusion on the other variables.
The predictive ability of the multivariable models was
assessed by computing the proportion of explained var-
iation due to Schemper and Henderson [9]. Further-
more, relative importance of variables was assessed by
omitting variables one-by-one from the multivariable
model as suggested by Heinze and Schemper [10].
Furthermore, we evaluated the predictive ability using
ten-fold cross-validation as follows: first, the data set
was randomly split into 10 approximately equally-sized
subsamples. Second, nine of the ten subsamples were
merged to form a training sample. Regression coeffi-
cients were estimated for the multivariable model
including all variables using the training sample, and
risk scores were predicted for the remaining tenth sub-
sample (the test sample). These risk scores were
obtained by inserting the estimated regression coeffi-
cients and the observed variable values of the test sam-
ple into the linear model equation. This second step was
repeated ten times in turn such that each subject once
appeared in the test sample and such was assigned a
cross-validated risk score. Third, the cross-validated risk
scores were stratified into quartiles and Kaplan-Meier
curves, 5-year survival rates and a log-rank test were
used to describe the association of risk scores with sur-
vival. The process was repeated, omitting gene expres-
sion variables from the model to assess if and to which
extent prediction worsens if gene-expression was not
accounted for. This ten-fold cross-validation was seen as
more appropriate than a single split-up into a training
set and a test set, as the former yields more accurate
results than the latter [11]. P-values < 0.05 were consid-
ered as indicating statistical significance. The statistical
software packages R 2.4.2 http://www.r-project.org and
SAS 9.1.3 (2003 SAS Institute Inc., Cary, NC) were used
for statistical graphics and analyses, respectively.
Results
Estrogen receptor status was determined as follows:
Using 207 samples, of which we had both, immunohis-
tochemical and gene expression results of ER, we deter-
mined a cut-off value of 0.4984 for the gene expression
to differentiate ER positive and ER negative tumors.
Using this value to judge the status of ER, the original
immunohistochemical data had a 19.2% false positive
and 26.5% false negative rate, respectively. All samples
in this study were re-evaluated for their ER status using
this cut-off value, which generated 116 negative and 133
positive tumors.
Expression data of EMP1, EMP2, EMP3 and PMP22
were obtained from all tumor samples. After log2 trans-
formation, the data presented normal distribution
(Table 1). The age of the patients at diagnosis (median:
58 yrs, range 27 - 89 yrs) and clinical data, including
tumor size (pT), differentiation grade (G), nodal status
(pN), and histological type of the tumors were analyzed
for possible correlations with expression of EMPs and
PMP22 (Table 1). Statistical analysis revealed a signifi-
cant inverse correlation of EMP2 and PMP22 expression
in tumor tissues with differentiation grade (p = 0.005
and p = 0.019, respectively). In addition, all gene expres-
sions showed significant direct correlation with positive
ER status. Expressions of EMP1, EMP2 and EMP3 had
no prognostic values either for disease-free survival
(DFS) or overall survival (OS) (Table 2 and 3). However,
expression of PMP22 was a strong prognostic factor for
outcome in a multivariable Cox regression model.
Patients with higher than median PMP22 gene expres-
sion had a 3.47 times higher risk to die of cancer than
patients with lower than median PMP22 expression
(Table 2). They also had a 1.77 times higher risk to
relapse than those with lower than median PMP22
expression levels (Table 3). These hazard ratio estimates
were adjusted by tumor size, ER, nodal status, differen-
tiation grade, and age of the patients (age only for over-
all survival). Results did not change materially if an
interaction of ER status with log of survival time was
added to the model in order to account for non-propor-
tional hazards of ER status (data not shown). No signifi-
cant interaction of the effect of PMP22 with any other
variables in the model was detected. Analysing log
PMP22 levels instead of PMP22 categories did not
improve the model fit, neither of the univariate nor of
the multivariable models. Furthermore, an exploratory
analysis evaluating as potential cut-off values all deciles
of PMP22 did not improve over the categorization at
the median PMP22 value.
The proportion of variation in time to tumor-specific
death explained by PMP22 expression and all covariates
was 22.3%. This value dropped by 6.5%, 6.7% and 6.7%,
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the multivariable model, respectively (Table 4). This
result suggests that these three variables are equally
important to predict mortality of breast cancer. In case
of DFS, pN, ER status, and gene expression of PMP22
account for 13.0% prediction. If pN, ER, and PMP22
gene expression was omitted from the model, than the
prediction will reduced by 7.9%, 4.0%, and 2.3%, respec-
tively, indicating the most contribution of pN for DFS
(Table 4).
No association of PMP22 gene expression with OS
and DFS was seen in unadjusted analyses using Kaplan-
Meier curves (Figure 1). The additional prognostic value
of PMP22 in multivariable models must therefore be
attributed to certain correlation of PMP22 expression
with other strong predictors. Indeed, PMP22 expression
is positively correlated with ER status (Table 1 p <
0.0001). Thus the effects of PMP22 expression and ER
status were compromised in unadjusted analyses. Similar
but weaker associations exist between PMP22 gene
expression and prognostic values of tumor size and
lymph node involvement. Therefore we have computed
adjusted survival curves from the multivariable Cox
models, which refer to the estimated survival of patients
with mean values on tumor size, lymph node involve-
ment, differentiation grade, age and ER expression, and
high or low PMP22 expression (Figure 1).
Cross validation of the 5-year survival rates showed
that the model including PMP22 expression has a
broader range of prediction, therefore a better discrimi-
nation of different risk groups than models excluding
PMP22 expression. This is true for both DFS and OS
(Table 5), showing that PMP22 has an additive value in
predicting survival after the diagnosis of breast cancer.
Discussion
PMP22 and EMPs were selected for the evaluation of
their prognostic values based on their higher expression
levels in invasive breast cell lines compared to non-inva-
sive ones. The invasiveness of these cell lines was deter-
mined by the ability of the cells to penetrate into a
collagen-fibroblast matrix [12]. Cell motility and the
capacity to invade into the surrounding tissues are pre-
conditions for tumor cells to metastasize. Genes that are
Table 2 Estimates of hazard ratios for tumor related-death
Univariate Analysis Multivariable Analysis
Variable* Hazard
Ratio
95% Confidence Interval Of Hazard
Ratio
p Hazard
Ratio
95% Confidence Interval of Hazard
Ratio
p
EMP1 1.11 0.69 - 1.77 0.6664
EMP2 0.82 0.59 -1.51 0.8223
EMP3 1.11 0.69 - 1.77 0.6703
PMP22 1.29 0.81 - 2.07 0.2851 3.47 1.82 - 6.62 0.0002
pT 1.58 1.10 - 2.26 0.0125 1.68 1.15 - 2.47 0.0078
pN 3.68 2.00 - 6.77 <0.0001 3.46 1.80 - 6.65 0.0002
G 1.03 0.72 - 1.47 0.8887 1.06 0.70 - 1.62 0.7741
Age 0.52 0.33 - 0.84 0.0069 0.58 0.34 - 0.98 0.0406
ER 0.53 0.33 - 0.84 0.0077 0.31 0.17 - 0.55 <0.0001
*The hazard ratios are indicated for: EMP1, EMP2, EMP3, and PMP22 (> median gene expression) vs. (≤ median gene expression);
(pT3+pT4) vs. (pT1+pT2); pN1 vs. pN0; (G2+G3) vs. G1; Age > 50 vs. Age ≤ 50; ER+ vs. ER
Table 3 Estimates of hazard ratios for recurrent disease
Univariate Analysis Multivariable Analysis
Variable* Hazard
Ratio
95% Confidence Interval of Hazard
Ratio
p Hazard
Ratio
95% Confidence interval of Hazard
Ratio
p
EMP1 1.01 0.69 - 1.47 0.9738
EMP2 1.03 0.70 - 1.50 0.8930
EMP3 0.93 0.64 - 1.36 0.7275
PMP22 1.01 0.69 - 1.46 0.9780 1.77 1.09 - 2.87 0.0200
pT 1.32 0.99 - 1.78 0.0610 1.27 0.93 - 1.74 0.1367
pN 2.72 1.73 - 4.27 <
0.0001
2.72 1.69 - 4.38 <
0.0001
G 1.06 0.78 - 1.44 0.7033 0.98 0.70 - 1.38 0.9133
ER 0.63 0.43 - 0.92 0.0169 0.49 0.31 - 0.78 0.0025
*The hazard ratios are indicated for: EMP1, EMP2, EMP3, and PMP22 (> median gene expression) vs. (≤median gene expression);
(pT3+pT4) vs. (pT1+pT2); pN1 vs. pN0; (G2+G3) vs. G1; ER+ vs. ER-
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cells but are highly activated in invasive cells could be
markers for prediction of tumor metastases. They could
also indirectly indicate the outcome of patients. Indeed,
we showed that patients with higher expression of
PMP22 in their tumors have both, worse DFS and OS,
suggesting that PMP22 is involved directly or indirectly
in the invasion process. Our study also suggests that
invasive and non-invasive cell lines provide a useful
model for searching for prognostic factors.
In this study, we did not only show that PMP22 gene
expression has prognosticv a l u eo nD F Sa n dO S ,w e
also showed that PMP22 gene expression is as powerful
as nodal status and ER status to predict mortality of
breast cancer patients by calculating the proportion of
explained variation. Traditionally, the prognostic values
of gene expression were only evaluated by multivariable
Cox regression model. The gain of including additional
prognostic factors was not well addressed. Even though
many new prognostic biomarkers have been reported,
quite often they don’t increase the predictive accuracy
when added to the established clinical predictive factors
[13]. By leaving out one of the three important prognos-
tic factors, namely PMP22 gene expression, pN, or ER,
the proportion of explained variations decreased equally,
demonstrating that PMP22 expression contributes
equally to prognosis as pN or ER status does. Therefore,
PMP22 has potential use in clinical practice.
Using cross validation, we compared the ranges of 5-
year survival rates of breast cancer patients between
models including and excluding PMP22 gene expression.
In these analyses, risk scores were stratified into quar-
tiles. The results show that by including PMP22 gene
expression into the prediction model, the accuracy of
the prediction was significantly increased. This indicates
that including of PMP22 gene expression into clinical
risk evaluation can refine the prognosis, again showing
the added value of PMP22 gene expression to prognosis.
It is of great interests to establish a prognostic score
including PMP22 gene expression values and other
know independent factors.
So far, expression and functions of PMP22 have been
well investigated in neuroscience. Abnormalities in
PMP22 can lead to various peripheral neuropathies [14].
Increased PMP22 expression was found in other pre-
malignant or malignant tissues, like pancreatic tissues
[15], osteosarcoma, and glioblastoma tissues [16,17].
However, little is known about the functions of PMP22
in human cancer. It is very interesting to further investi-
gate the possible functions of PMP22 in breast cancer
and to clarify its roles in tumor invasion, so that we can
better understand its prognostic impact.
Conclusions
In this study we show that breast cancer patients with
higher than median PMP22 gene expression had a 3.47
times higher risk to die of cancer than patients with
lower than median PMP22 expression. They also had a
1.77 times higher risk to relapse than those with lower
than median PMP22 expression levels. The analysis of
the proportion of explained variation suggests that gene
expression of PMP22, ER status and pN variables are
equally important to predict mortality of breast cancer.
Cross validation of the 5-year survival rates showed that
the model including PMP22 expression has a broader
range of prediction, therefore a better discrimination of
different risk groups than models excluding PMP22
expression. This is true for both DFS and OS, showing
Table 4 Proportion of explained variation (PEV)
Disease-free survival Overall survival
PEV Partial (%) Partial (%)
pN 7.9 6.7
ER 4.0 6.7
PMP22 2.3 6.5
pT 1.0 2.8
Age - 1.5
G 0.0 0.1
Figure 1 Kaplan-Meier curves comparing patients with high
and low PMP22 gene expression (dichotomized at the median).
1A. DFS, not adjusted; 1B. OS, not adjusted; 1C. DFS, adjusted
survival function from Cox model (comparing high and low PMP22
gene expression for patients with average values for T, pN, G, and
ER); 1 D. OS, adjusted survivor function from Cox model (comparing
high and low PMP22 gene expression for patients with average
values for T, pN, G, ER, and age).
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after the diagnosis of breast cancer.
Taking together, PMP22 gene expression is an inde-
pendent prognostic factor for disease-free and overall
survival for breast cancer patients. It contributes equally
to the prediction of cancer related death as estrogen
receptor status and nodal status. Including PMP22 gene
expression into a multivariable model including ER and
nodal status, the accuracy of the prediction can be
increased.
Functional studies on PMP22 in breast cancer should
be investigated to elucidate its roles in the progression
of breast cancer and to explain if it could be a therapy
target.
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Table 5 5-year survival rates calculated by cross validation
5-year DFS rate 5-year OS rate
Quartile (Risk Scores) with PMP22 without PMP22 with PMP22 without PMP22
1 (lowest risk) 88% 87% 98% 91%
2 (intermediate low risk) 63% 68% 87% 91%
3 (intermediate high risk) 59% 48% 74% 78%
4 (highest risk) 41% 47% 62% 59%
Rate difference (lowest to highest risk) 47% 40% 36% 32%
p = 0.001 p<0.0001
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